You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Androgen Receptor positive TNBC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting
Has Results
  • Androgen Receptor Positive
  • +5 more
  • Corona, California
  • +6 more
Jun 8, 2022

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Triple Negative Breast Cancer Trial in United States (GTx-024)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Fort Lauderdale, Florida
  • +6 more
Oct 29, 2020

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +17 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Breast Cancer Trial in Beijing, Zhengzhou, Changsha (EG017)

Not yet recruiting
  • Breast Cancer
  • Beijing, Benjing, China
  • +2 more
Dec 30, 2022

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Houston (procedure, drug,

Recruiting
  • Invasive Breast Carcinoma
  • +11 more
  • Axillary Lymph Node Dissection
  • +5 more
  • Houston, Texas
  • +1 more
Mar 10, 2022

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Breast Cancer Female, Triple Negative and Androgen Receptor Positive Trial in Caen (Darolutamide, Capecitabine)

Active, not recruiting
  • Breast Cancer Female
  • Triple Negative and Androgen Receptor Positive
  • Caen, France
    Centre François Baclesse
Jan 3, 2022

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,

Active, not recruiting
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Biomarker Analysis
  • +3 more
  • Birmingham, Alabama
  • +8 more
Feb 3, 2022

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Seviteronel-D (Seivteronel in combination with dexamethasone)
  • Docetaxel
  • (no location specified)
Sep 21, 2021

Breast Cancer, Metastasis Trial in New York (Abemaciclib, Bicalutamide)

Recruiting
  • Breast Cancer
  • Metastasis
  • New York, New York
  • +2 more
Oct 14, 2021

Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube Trial in United States (Enzalutamide)

Completed
  • Advanced Epithelial Ovarian
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Mar 4, 2022

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)

Recruiting
  • Triple Negative Breast Cancer
  • Chicago, Illinois
  • +5 more
Oct 31, 2022

Solid Tumor, Androgen Receptor Gene Overexpression Trial in Darlinghurst (SEVI-D (Seviteronel in combination with dexamthasone))

Terminated
  • Solid Tumor
  • Androgen Receptor Gene Overexpression
  • SEVI-D (Seviteronel in combination with dexamthasone)
  • Darlinghurst, New South Wales, Australia
    St Vincent's Hospital
Mar 2, 2021

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Manchester, Greater Manchester, United Kingdom
  • +6 more
Jan 5, 2023

Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in United States (TH1902)

Recruiting
  • Solid Tumor
  • +8 more
  • Los Angeles, California
  • +5 more
Jun 27, 2022

Metastatic Breast Adenocarcinoma, Breast Cancer Trial in Switzerland (CR1447)

Active, not recruiting
  • Metastatic Breast Adenocarcinoma
  • Breast Cancer
  • Aarau, Switzerland
  • +12 more
Feb 3, 2022